Skip to main content

Table 6 Adverse effects

From: Prophylactic NAC promoted hematopoietic reconstitution by improving endothelial cells after haploidentical HSCT: a phase 3, open-label randomized trial

  NAC group A (N=80) High-risk control group B (N=40)
Grades 1–2 Grade 3 Grade 4 Grade 5 Grades 1–2 Grade 3 Grade 4 Grade 5
Skina 25(31) 0 0 0 8(20) 0 0 0
Gastrointestinala 54(67) 16(20) 0 0 30(70) 7(18) 0 0
Hepatobiliary/pancreatica 14(17) 5(6) 0 0 5(13) 1(3) 0 0
Cardiac 12(15) 1(1) 0 0 7(18) 0 0 0
Renal/genitourinary 8(10) 0 0 0 6(15) 0 0 0
Infectionsb 5(6) 16(20) 0 3(4) 2(5) 8(20) 1(3) 1(3)
Nervous system disorders 2(3) 0 0 0 1(3) 0 0 0
  1. Grade 1–2 adverse events in more than 10 of patients and all grade 3–5 adverse events were recorded from enrollment to 60 days post-transplantation
  2. aExcluded the patients with GVHD
  3. bExcluded the patients with cytomegalovirusviremia and Epstein-Barr virus viremia